An observational study in Burkitt Lymphoma, sponsored by French Africa Pediatric Oncology Group. Recruiting at 7 sites in 6 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by French Africa Pediatric Oncology Group · Observational
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.
This is the 4th Burkitt's Lymphoma (LMB) study by the GFAOP group. This study hopes to include at least 14 Sub Saharian countries some of whom have never participated in a LMB study. The evaluation of improvement in early diagnosis should be possible in this study. The study hopes to be able to evaluate children earlier, with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for children with a stage IV disease. Starting from 2026 we now have the possibility of introducing rituximab into the treatment of African children with Burkitt lymphoma, starting from 15/03/2026. This amendment will prospectively evaluate the toxicity and effectiveness of adding rituximab to the current therapeutic recommendations. These results will be compared with those observed during the first years of implementation in two GFAOP units: specifically, the unit at CHU Yalgado Ouagadougou in Burkina Faso and CHU Treichville in Abidjan, Ivory Coast.
976 studies on the registry are indexed under Burkitt Lymphoma; 159 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 152 across 66 observational studies indexed under Burkitt Lymphoma.
Browse Burkitt Lymphoma studies →French Africa Pediatric Oncology Group is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All Children with a Burkitt's Lymhoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.
-
Exclusion Criteria:
Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.
An amendment has been added to give 4 injections during induction treatments as in the study in adults, that is to say 1 injection on D1 and D6 of each induction treatment, COPM or COPADM depending on the risk group in two centers. It is an amendment of the therapeutic recommendations "GFA LMB2019" which are the basis, the other centers will continue with this GFALMB2019 protocol as is
Other: OBSERVATIONAL
OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
Evaluation of the number of cases with local disease.
evaluating the initial clinical reports and later histological reports to confirm the diagnosis and the stage.
Time frame: 5 years
Evaluation of the number of cases by stage at the time of diagnosis.
evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis.
Time frame: 5 Years
Evaluating the treatment given.
Comparison of treatment given and recommended treatment.
Time frame: 5 Years
Evaluating the follow up after treatment.
How many children alive or dead after treatment
Time frame: 5 Years
Number of relapse cases
The evaluation and the treatment of relapse and outcome
Time frame: 5 years
Application of therapeutic recommendations
Evaluations of the correct application of recommendations
Time frame: 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2020 (actual). Primary completion is estimated for Dec 2028, 97 months after the start.
Of 21 observational studies under Burkitt Lymphoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 114. This study's planned 97 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Africa Pediatric Oncology Group